Hostname: page-component-8448b6f56d-42gr6 Total loading time: 0 Render date: 2024-04-19T20:03:22.926Z Has data issue: false hasContentIssue false
  • English
  • Français

Current Status of Cannabis Treatment of Multiple Sclerosis with an Illustrative Case Presentation of a Patient with MS, Complex Vocal Tics, Paroxysmal Dystonia, and Marijuana Dependence Treated with Dronabinol

Published online by Cambridge University Press:  07 November 2014

Stephen I. Deutsch ,
Richard B. Rosse ,
Julie M. Connor ,
Jessica A. Burket ,
Mary E. Murphy  and
Fiona J. Fox
Get access Rights & Permissions [Opens in a new window]

Abstract

Pain, spasticity, tremor, spasms, poor sleep quality, and bladder and bowel dysfunction, among other symptoms, contribute significantly to the disability and impaired quality of life of many patients with multiple sclerosis (MS). Motor symptoms referable to the basal ganglia, especially paroxysmal dystonia, occur rarely and contribute to the experience of distress. A substantial percentage of patients with MS report subjective benefit from what is often illicit abuse of extracts of the Cannabis sativa plant; the main cannabinoids include delta-9-tetrahydrocannabinol (Δ9-THC) and cannabidiol. Clinical trials of cannabis plant extracts and synthetic Δ9-THC provide support for therapeutic benefit on at least some patient self-report measures. An illustrative case is presented of a 52-year-old woman with MS, paroxysmal dystonia, complex vocal tics, and marijuana dependence. The patient was started on an empirical trial of dronabinol, an encapsulated form of synthetic Δ9-THC that is usually prescribed as an adjunctive medication for patients undergoing cancer chemotherapy. The patient reported a dramatic reduction of craving and illicit use; she did not experience the “high” on the prescribed medication. She also reported an improvement in the quality of her sleep with diminished awakenings during the night, decreased vocalizations, and the tension associated with their emission, decreased anxiety and a decreased frequency of paroxysmal dystonia.

Type
Case Report
Information
CNS Spectrums , Volume 13 , Issue 5 , May 2008 , pp. 393 - 403
Copyright
Copyright © Cambridge University Press 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Consroe, P, Musty, R, Rein, J, Tillery, W, Pertwee, R. The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur Neurol. 1997;38:44–48.Google Scholar
2.Chong, MS, Wolff, K, Wise, K, Tanton, C, Winstock, A, Silber, E. Cannabis use in patients with multiple sclerosis. Mult Scler. 2006; 12:646–651.Google Scholar
3.Clark, AJ. Ware, MA, Yazer, E, Murray, TJ, Lynch, ME. Patterns of cannabis use among patients with multiple sclerosis. Neurology. 2004;62:2098–2100.Google Scholar
4.Killestein, J, Hoogervorst, EL, Reif, M, et al.Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology. 2002;58:1404–1407.CrossRefGoogle ScholarPubMed
5.Zajicek, J, Fox, P, Sanders, H, et al.Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomized placebo-controlled trial. Lancet. 2003;362:1517–1526.Google Scholar
6.Zajicek, JP, Sanders, HP, Wright, DE, et al.Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry. 2005;76:1664–1669.Google Scholar
7.Fox, P, Bain, PG, Glickman, S, Carroll, C, Zajicek, J. The effect of cannabis on tremor in patients with multiple sclerosis. Neurology. 2004;62:1105–1109.CrossRefGoogle ScholarPubMed
8.Wade, DT, Makela, P, Robson, P, House, H, Bateman, C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler. 2004;10:434–441.CrossRefGoogle ScholarPubMed
9.Wade, DT, Makela, PM, House, H, Bateman, C, Robson, P. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler. 2006;12:639–645.CrossRefGoogle ScholarPubMed
10.Vaney, C, Heinzel-Gutenbrunner, M, Jobin, P, et al.Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Mult Scler. 2004;10:417–424.Google Scholar
11.Svendsen, K, Jensen, T, Bach, F. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomized double blind placebo controlled crossover trial. BMJ. 2004;329:253–260.Google Scholar
12.Iskedjian, M, Bereza, B, Gordon, A, Piwko, C, Einarson, TR. Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain. Curr Med Res Opin. 2007;23:17–24.Google Scholar
13.Rog, DJ, Nurmikko, TJ, Friede, T, Young, CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology. 2005;65:812–819.Google Scholar
14.Brady, CM, DasGupta, R, Dalton, C, Wiseman, OJ, Berkley, KJ, Fowler, CJ. An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis. Mult Scler. 2004;10:425–433.CrossRefGoogle ScholarPubMed
15.Freeman, RM, Adekanmi, O, Waterfield, MR, Waterfield, AE, Wright, D, Zajicek, J. The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS). Int Urogynecol. 2006;17:636–641.CrossRefGoogle ScholarPubMed
16.Hashiguchi, S, Ogasawara, N, Mine, H, Kawachi, Y. Multiple sclerosis with caudate lesions on MRI. Intern Med. 2001;40:358–362.Google Scholar
17.Lana-Peixoto, MA, Teixeira, AL. Simple phonic tic in multiple sclerosis. Mult Scler. 2002;8:510–511.CrossRefGoogle ScholarPubMed
18.Fernandez-Ruiz, J, Lastres-Becker, I, Cabranes, A, Gonzalez, S, Ramos, JA. Endocannabinoids and basal ganglia functionality. Prostaglandins, Leukotrienes and Essential Fatty Acids. 2002;66(2–3):257–267.Google Scholar
19.Muller-Vahl, KR. Cannabinois reduce symptoms of Tourette's syndrome. Expert Opin Pharmacother. 2003;4:1717–1725.CrossRefGoogle Scholar
20.Wilson, RI, Nicoll, RA. Endocannabioid signaling in the brain. Science. 2002;296:678–682.Google Scholar
21.Muller-Vahl, KR, Schneider, U, Koblenz, A, et al.Treatment of Tourette's syndrome with Δ9-tetrahydrocannabinol (THC): a randomized crossover trial. Pharmacopsychiatry. 2002;35 57–61.Google Scholar
22.Baker, D, Jackson, SJ, Pryce, G. Cannabinoid control of neuroinflammation related to multiple sclerosis. Br J Pharmacol. 2007;152:649–654.Google Scholar